A retrospective, observational study of dulaglutide and other GLP-1 receptor agonist in patients with type 2 diabetes

Trial Profile

A retrospective, observational study of dulaglutide and other GLP-1 receptor agonist in patients with type 2 diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Dulaglutide (Primary) ; Albiglutide; Exenatide; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2017 Results assessing diabetes-related resource utilization and costs over the same 6-month post-index period intType 2 diabetes treated with Dulaglutide vs. Exenatide Qw or Liraglutide, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 16 Sep 2016 Results (n=4451) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
    • 30 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top